Kornimate/medical-research-clean huggingface dataset:
digital therapeutics on inhalation medication adherence in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: digital therapeutics (dtx) is an evidence-based，clinically evaluated software to treat，manage，and prevent a broad spectrum of diseases and disorders according to digital therapeutics alliance，which may improve the adherence of patients with chronic obstructive pulmonary disease (copd) to use inhaled medication and reduce the risk of acute exacerbation. this study plans to carry out a randomized controlled trial (rct), using digital therapy to record and manage the behavior data of patients with copd in the process of using inhaler medication, and analyze the correlation between digital therapy of copd and patients' drug compliance and treatment effect.

chronic obstructive pulmonary disease (copd) is a major disease that causes death and disability worldwide. the world health organization (who) estimates that copd has become the third leading cause of death worldwide, accounting for 6% of the global total deaths in 2019. copd seriously affects the quality of life of patients and causes heavy economic burden to society and families. inhaled medication is the key treatment for copd, and the adherence of inhaled medication is closely related to the effect of disease control. studies have shown that incorrect and irregular use of metered-dose inhaler are very common in patients.previous studies have shown that patients using mobile phones to record respiratory symptom diaries, and send blood oxygen saturation, heart rate, body temperature and other data, as well as changes in medication and medical treatment to the portal, and doctors access the data online to identify potential acute exacerbation and take intervention measures, can reduce the risk of acute exacerbation of copd. the digital therapeutics of copd consists of patient mobile phone program, doctor management software and intelligent medication recorder. it develops a digital intervention plan for patients, helping patients intuitively and comprehensively understand the treatment plan and how to act through medication tracking reminder. it also helps doctors to view visualized patient medication, symptoms and other trend data online to understand the real treatment response of patients. this study take digital therapeutics as intervention to explore the correlation between digital therapy and patient medication adherence and treatment effect.

Eligibility criteria:
inclusion criteria: 1. fully understand and willing to sign the written informed consent; 2. local residents diagnosed copd by physician; 3. aged 40 and above; 4. plan to receive metered-dose inhaler as long-term treatment; 5. have a smartphone and can apply wechat applet after training; exclusion criteria: 1. certain comorbidities (e.g. unstable coronary complications); 2. undergone thoracic, abdominal or ophthalmic surgery in recent 3 months; 3. pregnant or lactating women; 4. abs allergy history.

Keywords: copd digital intervention inhalation medication adherence
dental appliance for parkinson's disease

Conditions: Parkinson Disease

Summary: the investigators are evaluating the immediate effect of a dental mouthpiece on gait and balance among people with parkinson disease as well as longer-term feasibility use and the effect of the mouthpiece on sleep and quality of life.

the investigators are conducting a pilot study with participants who have been diagnosed with parkinson disease recruited from the community. participants will attend one in-person visit and be custom fitted with a dental mouthpiece. participants will be asked to wear the mouthpiece as much as possible for one month including while sleeping and during the day, except while eating. participants will be asked to return for a second in-person visit to repeat gait and balance (motor) measures.

Eligibility criteria:
inclusion criteria: * have a diagnosis of idiopathic, typical parkinson disease according to the united kingdom brain bank criteria, hoehn \& yahr stages 1-3; * stable parkinson disease medications for the two weeks prior to baseline visit; * be able to walk at least 10 meters at baseline with or without an assistive device; * have their own teeth and/or dentures; * be willing to try to wear a mouthpiece for one month; * are over the age of 30; and * provide written or verbal informed consent. exclusion criteria: * pre-existing medical conditions that would inhibit full participation in the study's tasks; * absence of any dentition; * cognitive impairments indicated by mini mental status exam (mmse) score of \<24; * freezing of gait which moderately or severely impacts walking; or * current use of an oral appliance (e.g., a dental mouthpiece, retainer, or braces).
cutibacterium acnes in bone and joint infections

Conditions: Prosthesis and Bone Infections; Cutibacterium Acnes

Summary: prosthetic joint infections (pjis) are increasing with the use of orthopedic devices on an ageing population. cutibacterium acnes is a commensal organism that plays an important role in the ecosystem healthy human skin, yet this species is also recognized as a pathogen in foreign body infection: endocarditis, prostatitis and specifically in pjis. c. acnes is able to escape the immune system. this phenomenon could reflect two bacterial behavior: the bacterial internalization by host cells and the biofilm formation.

the aim of the study is to evaluate specific pathogenicity factors (ability to internalize bone cells and ability to form a biofilm) of bacteria derived from clinical strains of c. acnes isolated from bone infections on orthopedic material.

Eligibility criteria:
inclusion criteria: * bone infection with c. acnes, * isolation of the strain, * presence of a single species, * conservation of a viable strain, * patients over 18 years

Keywords: cutibacterium acnes prosthesis bone infections
light therapy to increase energy in adolescents and young adults newly diagnosed with solid tumors: a pilot study

Conditions: Neoplasms; Fatigue

Summary: fatigue is one of the most consistent and distressing symptoms reported by pediatric oncology patients. the investigators' work has demonstrated that in the period from diagnosis through the initial 8 weeks of treatment, adolescents and young adults with solid tumors experience substantial fatigue that is not related to sleep disruption. fatigue can contribute to many adverse outcomes including poor treatment adherence, reduced social activities, depressive symptoms, behavior problems, and poorer quality of life. unfortunately, no definitive intervention to reduce fatigue has been developed for pediatric oncology patients. investigators propose a study to estimate the feasibility and acceptability of bright light therapy as an intervention to decrease fatigue in adolescents and young adults who are newly diagnosed and receiving treatment for solid tumors, including lymphoma.

this feasibility and acceptability study will assess the rate of consent to, adherence to, and side effects from a therapy study in a randomized trial comparing bright white light (bwl) to dim red light (drl). four questionnaires will be distributed to patients and/or their parents, depending upon the questionnaire, to study the fatigue, quality of life, mood symptoms, and side effects of the bwl/drl intervention in adolescents and young adults being treated for solid tumors, including lymphoma. primary objectives: * to estimate the feasibility and acceptability of a bwl intervention compared to a drl standard comparison group in adolescent/young adult solid tumor and lymphoma patients. secondary objective: * to estimate the effect size of this intervention on measures of fatigue in order to design a larger clinical trial of efficacy of a randomized control trial of bwl versus drl intervention for fatigue in pediatric oncology patients. other prespecified objectives: * estimate the effect of participant location (inpatient, hospital-based housing, or home) on adherence. * estimate rates of depressive symptoms. * describe quality of life.

Eligibility criteria:
inclusion criteria: * age 12 years or older * has initiated treatment as part of an active st. jude children's research hospital (sjcrh) treatment plan * ≤ 30 days post diagnosis of a solid tumor or lymphoma * patient speaks, reads and writes in english or spanish * potential participant/guardian is willing to sign informed consent exclusion criteria: * blind or having a history of eye disease including, but not limited to, macular degeneration, or other diagnosed retinal problems * undergone laser corrective eye surgery in the past 30 days * significant physiological or psychological impairment that interferes with participation (e.g., migraines, bipolar disorder, psychosis, seasonal affective disorder) * recently started on anti-depressant medications (past one month for those on selective serotonin reuptake inhibitors \[ssri\] and past two months for those started on monoamine oxidase inhibitors \[maoi\])

Keywords: solid tumors
lactated ringer's and plasmalyte in critically ill adults

Conditions: Critical Illness

Summary: in recent years, there has been a large amount of literature reports that normal saline can increase the incidence of renal injury in critically ill patients compared with balanced salt solution.however, no studies have compared the effects of different types of balanced salt solutions on the incidence of renal injury.


Eligibility criteria:
inclusion criteria: * all patients admitted to icu exclusion criteria: * patients \<18 year old when admission * patients who stay less than 24 hours in icu * patients who do not sufficient data for further analysis * readmission patients during the study period
evaluation of novel cardio-pulmonary physiological monitor, the vqm phm™, for acute care medicine

Conditions: Elective Procedures Requiring Mechanical Ventilation

Summary: this is a prospective, observational study to assess agreement of pulmonary health parameters measured by a new non-invasive physiologic monitor, the vqm pulmonary health monitor (phm)™ with clinical gold standards.

the specific aim of this study is to evaluate the intermittent non-invasive measurements of pulmonary function: pulmonary blood flow (pbf), functional residual capacity (frc), shunt fraction index (qsi) and airway dead space measured by the vqm phm™ compared to known clinical standards. pbf will be compared to continuous and intermittent bolus thermodilution cardiac output as measured through a swan-ganz catheter. frc will be compared to an frc measurement provided by a standard nitrogen washout method. qsi will be compared to shunt fraction calculated through mixed venous and arterial blood gas values (vbgs/abgs). airway dead space will be compared to an airway dead space measurement provided by a ventilator.

Eligibility criteria:
inclusion criteria: * age greater than 18 years * scheduled for an elective surgical procedure with an anticipated duration of more than 2 hours requiring general anesthesia without the use of inhalation anesthetics * surgical procedure that requires pressure-controlled positive pressure ventilation using an endotracheal tube * surgical procedure that requires the use of intra-arterial pressure monitoring and/or a swan-ganz catheter for the monitoring of continuous cardiac output exclusion criteria: * patients who require ventilation tidal volumes less than 250cc * age less than 18 years * pregnancy * prisoners * surgical procedure which requires carbon dioxide (co2) insufflation * unable to tolerate a transient increase in inhaled co2 * unable to tolerate a transient increase in inhaled nitrous oxide (n2o) or use of n2o is contraindicated * patients who require a high fraction of inspired oxygen (fio2) (\>70%) to maintain a hemoglobin saturation (spo2\>98%) women, minorities or non-english speaking subjects will not be excluded

Keywords: physiologic monitors acute care medicine
research on operating handle of colonoscope

Conditions: Colonic Disease

Summary: artificial intelligence is deeply integrated with medical diagnosis, and intelligent colonoscopy technology has broad room for development. at present, the assist device of colonoscopy is insufficiently studied. it is the part that needs to be further explored in the development of artificial intelligence colon diagnosis and treatment technology. the study will be conducted at the digestive endoscopy center and it is expected that 380 subjects will participate voluntarily. subjects met: 1) routine colonoscopy; 2) willing to provide relevant information required by the experiment; 3) signed informed consent for the study. this topic focuses on the colonoscope assist device, through the combination of power assisting device, dynamic analysis, and migration expert skills, to achieve a combination of intelligent power and precise treatment, and establish a prototype of the patient-colonoscopy-assisted assist system-doctor's four-in-one diagnosis and treatment system.


Eligibility criteria:
inclusion criteria: 1. routine colonoscopy; 2. willing to provide relevant information required by this experiment; 3. sign the informed consent form for this study. exclusion criteria: 1. can not tolerate colonoscopy; 2. information about the requirements of this study cannot be provided; 3. questionnaires cannot be conducted.

Keywords: intelligence; colonocope; handle
intradialytic physiotherapy in patients with chronic kidney disease

Conditions: Chronic Renal Diseases

Summary: the objective is to evaluate in adult patients with chronic kidney disease the effect of neuromuscular electrical stimulation (nmes) in the upper limbs associated with a cycle ergometer in the lower limbs, during hemodialysis, on functional capacity and peripheral muscle strength. the hypothesis is that in people with chronic kidney disease on hemodialysis, the addition of neuromuscular electrical stimulation in the upper limbs associated with aerobic training of the lower limbs is superior to aerobic exercise alone in improving functional capacity, peripheral muscle strength, quality of life, safety intervention and patient adherence.

objective: to evaluate, in adult patients with chronic kidney disease, the effect of neuromuscular electrical stimulation (nmes) in the upper limbs associated with a cycle ergometer in the lower limbs, during hemodialysis, on functional capacity and peripheral muscle strength. methods. this is a controlled, randomized, double-blind, intention-to-treat clinical trial carried out at the cassiano antônio moraes university hospital (hucam). thirty individuals who will be randomly allocated to an intervention group (ie active nmes on upper limbs for 20 minutes and aerobic exercise on a cycle ergometer for 30 minutes) or a control group (ie nmes-sham on upper limbs for 20 minutes and aerobic exercise on a cycle ergometer for 30 minutes). the treatment will be carried out for 8 weeks, with 3 weekly sessions totaling 24 sessions. outcome measures will be collected by trained researchers before treatment (week 0) and at the end of treatment (week 9), always in the second hemodialysis session of the week. functional capacity, peripheral muscle strength, activity level of daily living, quality of life, intervention safety, patient compliance, hemodialysis filtration rate (kt/v) and renal function (potassium, phosphate and magnesium clearance) will be evaluated. impact. this study could potentially provide important information and assist in clinical decision making regarding the combined use of nmes with a cycle ergometer to optimize the clinical benefits of therapeutic exercise in patients with chronic kidney disease.

Eligibility criteria:
inclusion criteria: * have chronic kidney disease; * undergo hemodialysis at hucam for at least 3 months; * present a hemoglobin level \> 9 g/dl; * present clinical stability for at least 3 months; * do not participate in another physical exercise program; * present the ability to perform the assessment tests; * age equal to or greater than 18 years, and can be of both sexes; * accept to participate in the research by signing the informed consent form. exclusion criteria: * presents symptoms and/or health conditions (cardiovascular, respiratory, neurological, cognitive) that prevent the performance of evaluation tests and participation in the exercise program.

Keywords: chronic kidney disease hemodialisis exercise neuromuscular electrical stimulation
a study of tocilizumab in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is an open-label, uncontrolled, observational study in patients with rheumatoid arthritis (ra) who are receiving tocilizumab concomitantly with methotrexate as part of their standard of care.

this single arm, open label study evaluates the safety and pharmacodynamic profile of tocilizumab in ra patients. participating patients are among those for whom tocilizumab is indicated and who are scheduled to receive tocilizumab as part of their normal care, in full compliance with the fda-approved prescribing information. study assessments consist of clinical evaluations and laboratory tests conducted in conjunction with the first three monthly intravenous infusions of tocilizumab. these assessments are designed to provide a better understanding of the pharmacodynamic effects and mechanistic actions of tocilizumab and help guide the clinical development of other therapeutic agents for ra. a total of 15 patients are expected to participate for approximately 10 weeks.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * moderately to severely active rheumatoid arthritis * inadequate response to previous treatment with an anti-tnf agent * receiving methotrexate for at least 12 wks before study exclusion criteria: * previous treatment with tocilizumab * previous treatment with other il-6 receptor inhibitors * treatment with corticosteroids (oral prednisone \>10 mg/day or equivalent) within 4 wks * conditions noted in the tocilizumab prescribing information

Keywords: rheumatoid arthritis, tocilizumab
comparison the effect of smart phones addiction between children and adolescents on posture deviations , physical fitness and intelligence in egypt

Conditions: Smart Phone Addiction

Summary: comparison the effect of smart phones addiction between children and adolescents on posture deviations , physical fitness and intelligence in egypt


Eligibility criteria:
inclusion criteria: * subjects with the following criteria will be enrolled in this study : the participants will be from middle childhood to adolescents and their age will be ranged from 9to 18 years. they had body mass index (bmi) = 18.5 :40 . they have a score of 24 or more on the smart phones addiction scale-short version. exclusion criteria: * subjects will be excluded from the study if the participant has the followings that affect that study: visual or hearing defects, cachexia, any neurological disorders and musculoskeletal problems, any congenital abnormalities .
whole body fluorine f 18 sodium fluoride pet/ct scan and whole body mri in finding bone metastases in patients with prostate cancer

Conditions: Bone Metastases; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Summary: this phase 0 trial studies whole body fluorine f 18 sodium fluoride positron emission tomography (pet)/computed tomography (ct) scan and whole body magnetic resonance imaging (mri) in finding bone metastases in patients with prostate cancer. diagnostic procedures, such as whole body fluorine f 18 sodium fluoride pet/ct scan and whole body mri, may help find and diagnose bone metastases.

primary objectives: i. to evaluate the sensitivity and specificity of whole-body fluorine f 18 sodium fluoride pet/ct scan in detecting bone metastases in patients with high-risk prostate cancer using bone scan as the reference standard. ii. to evaluate the sensitivity and specificity of whole-body mri in detecting bone metastases in patients with high-risk prostate cancer using bone scan as the reference standard. outline: patients undergo technetium tc 99m methylene diphosphonate bone scan, fluorine f 18 sodium fluoride pet/ct scan, and whole-body mri for the detection of bone metastases. patients with discordant imaging results (negative bone scan and positive pet/ct scan and/or mri) undergo additional imaging at 6, 12, 18, and 24 months.

Eligibility criteria:
inclusion criteria: * any ethnic group * pathologically proven prostate cancer with high risk for bone metastases * rising prostate-specific antigen (psa) despite androgen deprivation therapy (adt), psa \> 10 ng/ml * ability to understand and the willingness to sign a written combined health insurance portability and accountability act (hipaa) and informed consent document * patients eastern cooperative oncology group (ecog) performance is =\< 1 exclusion criteria: * patients may not receive any other investigational therapeutic agents from within 7 days prior to study drug administration through 7 days following study drug administration * patients with known contraindications to mr imaging such as presence of mri incompatible devices such as pacemakers and certain aneurysm clips, severe claustrophobia, or any other condition which would preclude proximity to a strong magnetic field; this exclusion is a standard of practice * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; patients in this category are excluded to reduce medical risk to their safety and to avoid confounding variables in regard to the possibility of adverse events * patient is unable to tolerate or has a lifer threatening allergy to the radiopharmaceutical used for bone scan or 18f-fluoride pet
fentanyl transdermal matrix patch zr-02-01 to treat chronic, moderate to severe non-malignant pain

Conditions: Pain

Summary: the purpose of this study is to evaluate the safety of the matrix fentanyl patch zr-02-01 in providing relief of non-malignant chronic pain.

this study will evaluate the safety of the matrix fentanyl patch. the study will be conducted in opioid-tolerant patients with moderate to severe non-malignant chronic pain currently taking an around-the-clock opioid. patients will discontinue their current opioid regimen and begin using zr-02-01 as soon as possible under the direction of the physician investigator upon entry into the study. patient's dose of zr 02 01 will be determined by the investigator using sponsor-provided conversion. pain therapy will be under the supervision of the physician investigator.

Eligibility criteria:
inclusion criteria: * patient is at least 18 and no older than 75 years of age * patient has moderate to severe, non-malignant chronic pain that is expected to last for at least 12 months and is currently taking an around-the-clock opioid to treat his/her pain * patient is already receiving opioid therapy, has demonstrated opioid tolerance, and requires a total daily dose of opioids at least equivalent to 25 mcg/hr of transdermal fentanyl. patients who are considered opioid-tolerant are those who have been taking a daily dose of at least 30 mg of oral morphine or morphine equivalent opioid for at least 2 weeks. exclusion criteria: * patient has active cancer * patient has a history of substance abuse or has a substance abuse disorder

Keywords: chronic pain pain